Michael Brooks
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Michael Brooks is currently President at Edesa Biotech, Inc. since 2019, with employment at the company starting in 2015.
Former positions include Director-Business Development at Cipher Pharmaceuticals, Inc. from 2010 to 2015, President at Edesa Biotech, Inc. (Old), and Vice President-Corporate Development & Strategy at Edesa Biotech Research, Inc. Education includes an MBA from Rotman School of Management and undergraduate and doctorate degrees from the University of Toronto.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EDESA BIOTECH, INC. 3,28 % | 27.05.2026 | 291.479 ( 3,28 % ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| EDESA BIOTECH, INC. | Präsident | 07.06.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
| CIPHER PHARMACEUTICALS INC. | Corporate Officer/Principal | 01.01.2015 |
Edesa Biotech Research, Inc. | Corporate Officer/Principal | - |
Edesa Biotech, Inc. (Old)
Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Develops novel non-steroidal molecules for the treatment of allergic contact dermatitis | Präsident | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Cipher Pharmaceuticals, Inc.
Cipher Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Provides laboratory testing and medical imaging services | Health Technology |
Rotman School of Management
Rotman School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Edesa Biotech, Inc. (Old)
Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Develops novel non-steroidal molecules for the treatment of allergic contact dermatitis | Health Technology |
Edesa Biotech, Inc.
Edesa Biotech, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for treatment of chronic allergic contact dermatitis | Health Technology |
Edesa Biotech Research, Inc. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen